Achillion is a pharmaceutical company based in the USA that is carrying out research in to possible new drug treatments for C3G diseases. The recently launched C3G patient support program, WeC3G™ is sponsored by Achillion and can be found here: www.wec3g.com/
In addition links to information on Achillion’s C3G clinical trials including the sites that are planned, the sites that are open, and the contact information for these trials can be found below. They have a site open in Melbourne, Australia with plans to have clinical trial sites in the United Kingdom, United States, Belgium and Netherlands so far.
•Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G): clinicaltrials.gov/show/NCT03369236
•Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN: clinicaltrials.gov/show/NCT03124368
Get the latest
For up-to-date news and information visit our news or join our mailing list below:
View upcoming events and dates in our MPGN/DDD Support Group calendar.
Find out what we’re doing right now and how you can help: